Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study-Reference-Cited by-同舟云学术

Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study

Published:2022-12 Issue: Volume:194 Page:110187
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Kim Jinyoung,Han Kyungdo,Kim Bongsung,Baek Ki-Hyun,Song Ki-Ho,Kim Mee Kyoung,Kwon Hyuk-Sang

Funder

National Health Insurance Service

National Research Foundation of Korea

Ministry of Science, ICT and Future Planning

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference39 articles.

1. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings

2. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications;Fabbrini;Hepatology,2010

3. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012;142:711–25 e6. doi: 10.1053/j.gastro.2012.02.003.

4. The natural history of nonalcoholic fatty liver disease: a population-based cohort study;Adams;Gastroenterology,2005

5. State-of-the-art overview of the pharmacological treatment of non-alcoholic steatohepatitis;Cho;Endocrinol Metab (Seoul),2022

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between hypoglycemic agent use and the risk of occurrence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus;PLOS ONE;2023-11-22

2. Risk of Pancreatic Cancer and Use of Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matching Analysis;Endocrinology and Metabolism;2023-08-31

3. Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update;Expert Opinion on Drug Metabolism & Toxicology;2023-08-03

4. Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice;Diabetes, Metabolic Syndrome and Obesity;2023-08

5. Comparative effects between old and new antidiabetic agents on metabolic- associated fatty liver disease (MAFLD);Diabetes Epidemiology and Management;2023-07